Generic Name: Alirocumab
Brand Name: Praluent
Manufacturer: Sanofi-aventis Canada Inc.
Therapeutic Area: Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Indications: Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Submission Type: Initial
Project Status: Complete
Date Recommendation Issued: July 20, 2016
Recommendation Type: Reimburse with clinical criteria and/or conditions